Hints and tips:
Related Special Reports
Related Topics
...That prompted Shionogi in late October to upgrade its annual guidance for domestic sales of Xocova, while it lowered its target for international sales....
...Shionogi participated in the pilot....
...ViiV, a GSK majority-owned venture with Pfizer of the US and Japan’s Shionogi, told investors last week that it had raised its sales growth projection to between 6 and 8 per cent between 2021 and 2026, as...
...The model would also be expanded to Scotland, Wales and Northern Ireland, after the success of the pilot between NHS England and two drugmakers — Pfizer of the US and Japan’s Shionogi....
...The pilot started with drugs developed by Pfizer and Japan’s Shionogi last year....
...A new antiviral from Japan’s Shionogi has received fast-track designation by the US regulator. Yet Pfizer has forecast a steep drop in Paxlovid sales this year....
...The rally came after a difficult January for Shionogi shares, which lost nearly 20 per cent during the month....
...Just maintaining Shionogi’s manufacturing plant for its antibiotic drug will require about $100mn in revenue a year....
...Japanese drugmaker Shionogi has also shown promising results for its oral antiviral, which rapidly cleared the virus in a mainly vaccinated population....
...Under the deal being struck by the NHS with Pfizer of the US and Shionogi of Japan, the drug companies will be paid a fixed fee of £10mn a year....
...The UK has a pilot project to provide guaranteed revenue to two new antibiotics, developed by Shionogi and Pfizer, that treat severe drug-resistant infections....
...Japanese pharmaceutical company Shionogi has begun a phase 1 trial of an antiviral pill for Covid-19 patients with minor symptoms, joining peers worldwide in seeking a therapy to treat infected people at...
...Sales of a third antiviral made by Japanese pharma company Shionogi are estimated at $0.5bn, down from $2.5bn, because of delays in the approval of the treatment....
...The pilot scheme announced on Tuesday will initially offer Pfizer of the US and Shionogi of Japan contracts capped at £10mn a year each, to supply a new antibiotic for up to 10 years....
...It will pay Shionogi £20m for the molecule, a further £15m when clinical development milestones are met, plus royalties on net sales. Shionogi will make capped contributions to the development....
...GlaxoSmithKline said late on Monday that US drug regulators had approved use of cabotegravir, a long-acting injectable drug made by ViiV Healthcare, which is majority owned by GSK and also backed by Pfizer and Shionogi...
...“There is no best model yet,” says Isao Teshirogi, president of Shionogi, the Japanese pharmaceutical company, which is also participating in the UK pilot with its drug, Cefiderocol....
...Japanese groups Shionogi and Daiichi Sankyo, which are developing Covid vaccines, are shifting research towards the new variant. For now, Chinese companies have an edge over regional competitors....
...Shionogi has been carrying out its trial since December. If its vaccine receives special conditional approval, the treatment might be rolled out before year-end, the company said....
...Pfizer is working on a similar drug, as is Japanese drugmaker Shionogi & Co....
...Treatments: Japan’s Shionogi shared positive trial results for its Covid-19 pill. Covid cases and vaccinations Get the latest worldwide picture with our vaccine tracker And finally . . ....
...She is now head of R&D at ViiV Healthcare, an HIV-focused pharmaceuticals company majority-owned by GlaxoSmithKline with Pfizer and Shionogi as shareholders....
...UMN Pharma now stands in negative net worth and under the wing of fellow Japanese pharma company Shionogi....
...The UK recently selected two antimicrobials — made by Japan’s Shionogi and the US’s Pfizer — to be purchased via this Netflix-style subscription payment model....
...The Shionogi boss also cast doubt on aggressive timetables and production targets set by rivals....
International Edition